Recent studies have shown a relationship between elevated CRMP-2 and epilepsy, including the usage of lacosamide, a CRMP-2 antagonist, in the treatment of refractory partial epilepsy seizures (Wilson and Khanna, 2015; Keren-Aviram et al., 2018). Here, DPYSL2 is linked to epilepsy.